Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.
 

Epigenetic Targeting to Deplete Cytostatic Breast cancer cells under Endocrine Therapy

Loading...
Thumbnail Image

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Epigenetic Targeting to Deplete Cytostatic Breast cancer cells under Endocrine Therapy

Published Date

2021-08

Publisher

Type

Thesis or Dissertation

Abstract

Approximately 70% of breast cancer are hormone receptor-positive, which express estrogen receptors (ER) and are dependent on estrogen to grow. Hormonal therapies using selective estrogen receptor modulators, such as tamoxifen, are frequently used to treat ER+ breast cancer. Tamoxifen treatments have shown efficacy in managing ER+ breast cancer, but approximately 30% of patients relapse even after prolonged remission. Tamoxifen can suppress the growth of ER+ breast cancer cells and arrest them in a cytostatic state, but the cytostatic cancer cells require continual maintenance and constitute a persistent reservoir from which resistant cell clones and relapses can emerge. Depleting such persistent cytostatic cancer cells could improve treatment outcomes but targeting cancer cells in non-proliferating state has been elusive. Our laboratory has recently performed a small molecule screen with an epigenetic compound library on an ER+ breast cancer cell line and identified histone deacetylases (HDACs) as candidates for targeting persistent cytostatic cancer cells under hormonal therapy. In this thesis, I worked with other members in the laboratory to determine the efficacy and selectivity of clinical-grade HDAC inhibitors in depleting persistent cytostatic breast cancer cells under tamoxifen treatments and explore the underlying targeting mechanisms. We showed a dose-dependent efficacy of multiple HDAC inhibitors in inducing apoptosis in different tamoxifen-mediated cytostatic breast cancer cell models. Importantly, HDAC inhibition showed low toxicity in normal non-proliferating mammary cells, highlighting the selectivity of the targeting approach. On-going mechanistic study suggested that HDAC inhibition in the tamoxifen-induced cytostatic cancer cells promotes the accumulation of acetylated histone and induce apoptosis by upregulating the proapoptotic protein BIM at both mRNA and protein levels. Together, this work underscores a therapeutic opportunity for depleting persistent cytostatic breast cancer cells under hormonal therapy and established HDACs as candidates for targeting.

Keywords

Description

University of Minnesota M.S. thesis August 2021. Major: Pharmacology. Advisor: Cheuk Leung. 1 computer file (PDF); v, 37 pages.

Related to

Replaces

License

Series/Report Number

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Other identifiers

Suggested citation

Jain, Ashika. (2021). Epigenetic Targeting to Deplete Cytostatic Breast cancer cells under Endocrine Therapy. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/259545.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.